Biotechnology News and Research

RSS

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

HST Global plans to develop new Clinical Treatment Facility in Ecuador

HST Global, Inc. today announced that it has targeted Ecuador for development of a Clinical Treatment Facility.

3 Feb 2010

10 new kits available for fast and simple isolation of nucleic acids from blood, plasma and serum

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of 10 new kits for the fast and simple isolation of nucleic acids from blood, plasma and serum, including circulating nucleic acids.

3 Feb 2010

Pall launches Leukotrap Affinity Plus Prion and Leukocyte Reduction Filter System

Pall Corporation, a global leader in filtration, separation and purification, today announced the launch of the Leukotrap® Affinity Plus Prion and Leukocyte Reduction Filter System. The new blood filter reduces prions and leukocytes in a single step.

From Pall Corporation 3 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.

3 Feb 2010

Celsis IVT alleges patent infringement, files lawsuit against Sekisui Chemical and subsidiaries

Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.

3 Feb 2010

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Teva’s Biologics License Application (BLA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

2 Feb 2010

Mary Ann Liebert launches Videourology journal for urologists

Videourology- is the first and only videojournal for urologists, publishing fully peer-reviewed surgical and micro-invasive video demonstrations of the latest techniques and technologies used to optimize surgical patient care.

2 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

AHM completes acquisition of Advogent Group

Advanced Health Media, LLC (AHM), the leading U.S. provider of pharmaceutical sales, marketing and compliance technology and services, announced it has acquired substantially all of the assets of Advogent Group, Inc. (Advogent), a Piscataway, NJ-based provider of marketing services for the pharmaceutical industry.

2 Feb 2010

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.

2 Feb 2010

Researchers identify 1.1M base pairs of DNA in soybean genome

In 2009, soybeans represented an almost $30 billion industry in the U.S. alone, making soybeans the second-most profitable crop next to corn. Worldwide, soybeans have been used in human foods and livestock feed for centuries and have been a key component in industrial products, such as plastics and soy biodiesel, an environmentally friendly fuel.

2 Feb 2010

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA.

2 Feb 2010

BRAIN, Bayer Schering Pharma collaborate in production process optimisation of steroid compounds

BRAIN AG, an European leader in white biotechnology and the global top 10 pharmaceutical corporation Bayer Schering Pharma AG co-operate in the field of production process optimisation of steroid compounds. The goal of the collaboration is the energy-efficient and thus sustainable fermentative production of steroid compounds using optimised microbial production strains taking plant derived raw materials as starting material.

2 Feb 2010

First annual Translational Regenerative Medicine Forum to be held in Winston-Salem

The Regenerative Medicine Foundation today announced the first annual Translational Regenerative Medicine Forum to be held April 6-8, 2010 at the Benton Convention Center in Winston-Salem.

2 Feb 2010

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Mentor Capital, Inc.'s first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.

2 Feb 2010

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

A new therapeutic made from tobacco plants has been shown to arrest West Nile virus infection, according to a new study by Arizona State University scientist Qiang Chen and his colleagues.

2 Feb 2010

EPO to grant patent notice to BioMimetic Therapeutics

BioMimetic Therapeutics, Inc. announced today the European Patent Office (EPO) intends to grant patent application No. 05803356 titled “Platelet-Derived Growth Factor Compositions and Methods of Use Thereof”.

2 Feb 2010

SDI selected for third consecutive time as key monoclonal antibody provider

SDI (Strategic Diagnostics Inc.), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, today announced it has been selected again by Science Applications International Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute’s “Clinical Proteomic Technologies for Cancer” initiative (CPTC: http://proteomics.cancer.gov).

2 Feb 2010

Biotechnology News and Research

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

HST Global plans to develop new Clinical Treatment Facility in Ecuador

10 new kits available for fast and simple isolation of nucleic acids from blood, plasma and serum

Pall launches Leukotrap Affinity Plus Prion and Leukocyte Reduction Filter System

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Celsis IVT alleges patent infringement, files lawsuit against Sekisui Chemical and subsidiaries

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Mary Ann Liebert launches Videourology journal for urologists

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

AHM completes acquisition of Advogent Group

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Researchers identify 1.1M base pairs of DNA in soybean genome

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

BRAIN, Bayer Schering Pharma collaborate in production process optimisation of steroid compounds

First annual Translational Regenerative Medicine Forum to be held in Winston-Salem

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

EPO to grant patent notice to BioMimetic Therapeutics

SDI selected for third consecutive time as key monoclonal antibody provider

Biotechnology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News